Back
EHRA Premium Access

Analysis of predictive factors for propafenone proarrythmia. Does exercise ECG play a role during long term propafenone treatment?

Session: Poster session 2 - Arrhythmias
Topic: Antiarrhythmic Drug Treatment
Speaker: Mr P. Kalmar (Debrecen, HU)
Event: EHRA 2019

Congress Presentation

Add to my library

Like

About the speaker

Mr Peter Janos Kalmar

University of Debrecen, Debrecen (Hungary)
0 follower

6 more presentations in this session

Comparison of the efficacy and safety of injectable propafenone and amiodarone for elimination of paroxysmal atrial fibrillation in patients without organic heart disease.

Speaker: Doctor A. Tarasov (Moscow, RU)

Access
Abstract
Like
Thumbnail

Effect of efficient lipid-lowering atorvastatin therapy on heart rate variability in the post-infarction period

Speaker: Professor V. Oleinikov (Penza, RU)

Access
Like
Thumbnail

QT dispersion in patients with myocardial infarction and high-dose therapy with atorvastatin

Speaker: Professor V. Oleinikov (Penza, RU)

Access
Like
Thumbnail

Antiarrhythmic relevance of inhibiting cardiac and non-cardiac sodium channel isoforms for the suppression of torsades de pointes arrhythmias in the chronic av block dog

Speaker: Mr A. Bossu (Utrecht, NL)

Access
Abstract
Like
Thumbnail

Venous thrombosis in patients after catheter ablation.Efficacy and safety of enoxaparin therapy with the transition to warfarin and monotherapy with rivaroxaban

Speaker: Miss A. Loginova (Moscow, RU)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Poster session 2 - Arrhythmias

Speakers: Mr P. Kalmar, Doctor A. Tarasov, Professor V. Oleinikov, Professor V. Oleinikov, Mr A. Bossu...
Access
Like
Thumbnail

About the event

Image

EHRA 2019

17 March - 19 March 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources